Amsel Medical Achieves Major Milestone with $7.45M Contract
Amsel Medical Corporation has recently announced a significant achievement in its mission to enhance trauma care. The company has been awarded a $7.45 million Phase III Small Business Innovative Research (SBIR) contract aimed at developing its innovative Temporary Vascular Occlusion Clamp (TVOC). This contract, funded by the United States Air Force, marks a pivotal moment for Amsel Medical as it endeavors to commercialize cutting-edge technology designed to control hemorrhages in emergency situations.
Revolutionizing Hemorrhage Control for Military and Civilian Settings
The awarded contract is a testament to Amsel Medical's progress, building upon previous successes with the Air Force through Phase I and II SBIR contracts. The aim of this Phase III contract is to accelerate the commercial availability of Amsel's groundbreaking haemorrhage control solution, known as SCureTO™. This device promises to revolutionize combat casualty care by providing crucial capabilities to military personnel and responders in urgent situations.
SCureTO™: A Breakthrough Device
SCureTO™ is designed to be deployed rapidly and minimally invasively in emergency settings. By allowing for arterial clamping upstream of injuries via a needle, the device seeks to address acute bleeding in a less intrusive manner. This is especially important in cases of non-compressible junctional injuries, providing a significant advantage in the field. The SCureTO™ device allows emergency responders to fine-tune the vessel occlusion and the flow of blood beyond the injury, which helps mitigate the risks associated with long-term limb ischemia and reduces the likelihood of reperfusion injury. Most critically, it extends the 'golden hour' for patients, enhancing their chances of survival and successful evacuation.
The Importance of Addressing Hemorrhage
Hemorrhage is known to be the leading cause of preventable death in military environments, accounting for up to 90% of such deaths. In civilian trauma cases, it ranks as the second leading cause. This makes the need for effective hemorrhage control solutions all the more pressing. Amsel Medical's commitment to reducing fatalities in both military and civilian contexts is reflective of its overarching mission: "Saving Limbs and Saving Lives." The SCureTO™ device stands to fulfill this mission by providing a critical resource that is both efficient and effective.
Insights from Leadership
James A. Heinz, CEO of Amsel Medical, shared his perspective on the importance of this advancement. He emphasized that trauma fatalities often occur before victims reach the hospital, highlighting the urgency for devices like SCureTO™ that can be deployed in the field. With military and civilian environments facing unique challenges, this device aims to bridge the gap in hemorrhage control capabilities, thereby saving both limbs and lives.
Expert Opinions on Future Operations
Colonel (ret) John Dorsch, a former surgeon general of the U.S. Air Force’s 24th Special Operations Wing, also commented on the potential of the SCureTO™ device. He underscored its innovative approach to controlling junctional hemorrhaging, which is often difficult to manage with traditional external tourniquets. According to him, its ability to act swiftly and effectively in non-surgical scenarios will be invaluable in future military operations, where every second counts.
Amsel Medical: Company Overview
Amsel Medical Corporation, based in Cambridge, Massachusetts, specializes in developing medical devices that focus on precision clamping technologies. Their aim is to provide reliable solutions for vessel occlusion through their innovative products, including SCureTO™ and the permanent implant SCureClamp™. The company is dedicated to advancing trauma care technology, thereby enhancing the safety and efficacy of medical responses in both military and civilian environments.
Frequently Asked Questions
What is the SCureTO™ device?
The SCureTO™ is a precision hemorrhage control solution designed for rapid and minimally invasive arterial clamping, aimed at controlling bleeding in trauma patients.
Who awarded Amsel Medical the contract?
The United States Air Force awarded Amsel Medical the $7.45 million Phase III SBIR contract.
What is the main goal of Amsel Medical?
Amsel Medical's core mission is to enhance trauma care by developing innovative medical devices that save limbs and lives.
How does SCureTO™ benefit trauma patients?
The device allows for effective hemorrhage control, extending the critical 'golden hour' for evacuation and treatment, which can significantly improve survival rates.
What are the future prospects for Amsel Medical?
With the recent contract, Amsel Medical is poised to accelerate the commercialization of its advanced trauma care solutions, potentially transforming medical responses in various situations.
